RT Journal Article
T1 Association between Polyphenol Intake and Breast Cancer Risk by Menopausal and Hormone Receptor Status
A1 Vitelli Storelli, Facundo
A1 Zamora Ros, Raul
A1 Alguacil Ojeda, Juan
A1 Fernández Villa, Tania
AB There is limited evidence of phenolic compounds acting as protective agents on severalcancer types, including breast cancer (BC). Nevertheless, some polyphenol classes have not beeninvestigated and there is a lack of studies assessing the effect on menopausal status and hormonereceptor status as influenced by these compounds. The objective of this study is to evaluate theassociation between the intake of all polyphenol classes in relation to the BC risk by menopausaland hormone receptor status. We used data from a population-based multi-case-control study(MCC-Spain) including 1472 BC cases and 1577 controls from 12 different regions of Spain. The oddsratios (ORs) with 95% CI were calculated using logistic regression of mixed effects by quartiles andlog2 of polyphenol intakes (adjusted for the residual method) of overall BC, menopausal and receptorstatus. No associations were found between total intake of polyphenols and BC risk. However,inverse associations were found between stilbenes and all BC risk (ORQ4 vs. Q1: 0.70, 95%CI: 0.56–0.89,Ptrend = 0.001), the consumption of hydroxybenzaldehydes (ORQ4 vs. Q1: 0.75, 95%CI: 0.59–0.93,Ptrend = 0.012) and hydroxycoumarins (ORQ4 vs. Q1: 0.73, 95%CI: 0.57–0.93; Ptrend = 0.005) were alsoinversely associated. The intake of stilbenes, hydroxybenzaldehydes and hydroxycoumarins cancontribute to BC reduction risk on all menopausal and receptor statuses.
PB MDPI
SN 2072-6643
YR 2020
FD 2020-04
LK http://hdl.handle.net/10272/18266
UL http://hdl.handle.net/10272/18266
LA eng
NO Vitelli Storelli, F., Zamora Ros, R., Fernández Villa, T., ... Alguacil Ojeda, J. (2020). Association between Polyphenol Intake and Breast Cancer Risk by Menopausal and Hormone Receptor Status. Nutrients, 12(4), 994. DOI: https://doi.org/10.3390/nu12040994
NO The study was partially funded by the “Accion Transversal del Cancer", approved by the SpanishMinistry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533,PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada,PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715,PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034), by the Fundación Marquésde Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-GenomeProject is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto deSalud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), bythe Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009,PI-0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10),by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejeríade Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, bythe Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government- Agency forManagement of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, by the FundaciónCaja de Ahorros de Asturias and by the University of Oviedo. and IDIBELL is aare members of the CERCAProgramme, Generalitat de Catalunya. RZ-R was supported by the “Miguel Servet” program (CP15/00100) fromthe Institute of Health Carlos III (Co-funded by the European Social Fund (ESF)—ESF investing in your future).
DS Repositorio Institucional de la Universidad de Huelva
RD 30 may 2026